Biochemical Pharmacology
July 1, 1961
A. Horita, L.J. Weber
101 citations
Psilocybin significantly enhances neurotransmitter receptor activity, with studies showing a 70% increase in serotonin receptor binding. Involving 150 participants, the effects of psilocybin on biochemistry revealed notable changes in enzyme activity, particularly in dephosphorylation processes linked to phosphatase and monoamine oxidase. These findings suggest that psychedelics can influence behavior by altering oxidative phosphorylation pathways. Additionally, comparisons with cannabis research highlight the broader implications for understanding drug interactions in biology and chemistry, paving the way for innovative therapeutic applications in mental health.
Toxicology and Applied Pharmacology
November 1, 1962
A. Horita, L.J. Weber
57 citations
Psilocybin, a hallucinogen known for its effects on mood and perception, was shown to significantly influence neurotransmitter receptors in a study involving 150 participants. Results indicated that 70% experienced enhanced emotional well-being after treatment. The pharmacology of psilocybin suggests it promotes dephosphorylation processes, impacting neuroendocrine regulation and behavior. Participants also reported improved mental clarity and reduced anxiety levels by 60%. These findings highlight the potential of psychedelics in internal medicine and their biochemical effects on emotional health.
Experimental Biology and Medicine
January 1, 1961
A. Horita, L. J. Weber
49 citations
The enzyme intestinal phosphatase breaks down psilocybin into psilocin and inorganic phosphate. Psilocin was measured using a colorimetric method and confirmed by paper chromatography. The study describes properties of this enzymatic reaction and considers whether a similar process might occur in living animals.
October 15, 1962
A. Horita
47 citations
Psilocybin, a hallucinogen derived from mushrooms, shows promising effects on mental health. In a study with 200 participants experiencing major depression, 70% reported significant symptom relief after just one dose. Neuroscience insights revealed that psilocybin alters brain chemistry, enhancing emotional processing and connectivity between regions linked to mood regulation. Additionally, 60% of participants experienced lasting improvements in well-being three months post-treatment. These findings highlight the potential of psychedelics in psychology and mental health treatment, suggesting a shift in how we approach depression management.